Rare Diseases Foundation Céline Hubert Pr Nicolas Lévy www.fondation-maladiesrares.org.

Slides:



Advertisements
Similar presentations
¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France
Advertisements

Making dementia a European priority Marseille – 17 October 2008 Jean Georges, Executive Director.
GASP Vision The Georgia Association of Sleep Professionals is the leader in Georgia for setting standards and promoting excellence in sleep medicine care,
Vice-rector of research department A.S. Karakushikova Director of Research and Education activities of Academic and Research Institution of Fundamental.
Dr. Joan Lluis Vives-Corrons Head of ENERCA project Head of the Red Cell Pathology Unit Hospital Clínic - IDIBAPS of Barcelona “ Rare Diseases a model.
Oakland University William Beaumont School of Medicine.
A L I M E N T A T I O N A G R I C U L T U R E E N V I R O N N E M E N T INRA: for the Earth and for Man Public mission oriented research Sustainable agriculture.
Research & Innovation International Rare Disease Consortium: Data Sharing Policy 3 rd International Traumatic Brain Injury Research Meeting Catherine BERENS.
Centre National pour la Recherche Scientifique et Technique CNRST TEER Unité des Technologies et Économie des Énergies Renouvelables Existing institutions.
28 – 29 September 2011 Vedic Village Spa Resort Kolkata, India. Mohammad Dauod Khuram MD, MPH National Manager, Health Program Aga Khan Foundation, Afghanistan.
Proposal for a European Faculty of Regenerative Medicine ScanBalt Campus Knowledge centers.
The evaluation of research units at HCERES
National Science Portals: New Potential Partnerships for Global Discovery Eleanor G. Frierson Deputy Director, National Agricultural Library (U.S.), Co-chair.
« How to succeed in doing a cluster strategy? » DICK Marie-Noëlle Cluster software.brussels.
Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.
SOS DESMOIDE ASSOCIATION Marie Podevin CTOS Meeting November 21 st, Boca Raton, Florida.
Paediatric Palliative Care and Policy Development Dr Chantal Wood Chair EAPC Paediatric Taskforce National Health Ministry PPC Taskforce Head of the Paediatric.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
HRSA’s Oral Health Goals and the Role of MCH Stephen R. Smith Senior Advisor to the Administrator Health Resources and Services Administration.
THE FRENCH NATIONAL CANCER INSTITUTE (INCa) Focusing care on patients The patient Committee.
PRESENTATION TO THE GOVERNOR’S COMMISSION The Health Care (R)Evolution: How FLHCC Employer Members Are Improving Value and Quality in Health Care Karen.
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
______________________________________________ Loïc Bordais Head of industrial liaison office Partnership management : Using decision support tools
Virtual Collaborative Social Living Community for Elderly Kick Off Event Inova+ Overview Diana Magalhães.
The Role of Research in Osteopathic Medical Education American Association of Colleges of Osteopathic Medicine June 25, 2004 David B. Moore Associate Vice.
The Concept of the European Platform of Women Scientists An instrument of support and a way to become active in the policy debate Isabel Beuter, M.A. Center.
ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )
RTD-B.4 - Regions of Knowledge and Research Potential Regional Dimension of the 7th Framework Programme Regions of Knowledge Objectives and Activities.
Telematikplattform für Medizinische Forschungsnetze (TMF) e.V. TMF – A Common Platform for Medical Research Networks in Germany Improving the Organisation.
The Danish Industrial PhD Programme Promoting research and innovation.
S&T and Innovation Policy in the Republic of Armenia Innovation Programs Division, SCS RA “Development of Coherent Innovation Policy in South Caucasian.
© CNRS / Dircom / March 2013 PRESENTING CNRS. © CNRS / Dircom / March 2013 P. 01 ● I CNRS is a scientific and technological public organization under.
A Model for Translating Research into Practice in the United States - Mexico Border Region Howard J. Eng, MS, DrPH Director, Southwest Border Rural Health.
Tony, Yen-Huei Tarn, M.S., Ph.D. President, TaSPOR Introduction of Taiwan Society for Pharmacoeconomics and Outcomes Research (TaSPOR) ISPOR 2ND ASIA-PACIFIC.
D.Zucker Draft-EB09 Ethics & Academic Technology Transfer: Patients, Products and Public Trust Deborah Zucker, MD, PhD, Tufts Medical Center.
Welcome to the 10 th Anniversary Meeting of the St. Louis Diabetes Coalition December 4, 2008.
Cradle to Cradle Network Interregional Steering Committee INTERREG IV C Programme Brief presentation Partner 9 - North-East RDA, Romania Brussels, 8-9.
Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.
The Power of the Rare Disease Community… Diane Dorman Vice President, Public Policy National Organization for Rare Disorders (NORD) 1 st International.
Send correspondence to: Bartha Maria Knoppers Chair of Interim Board Centre de recherche en Droit Public Université de Montréal.
+ Role of Industry in Clinical Care, Research, and Education.
Public Health Preventive Medicine and Epidemiology Prof. Ashry Gad Mohammed MB, ChB. MPH, Dr P.H Prof. of Epidemiology College of Medicine King Saud University.
Objective the aim of this project was directly addressing a major health problem for Jordan by producing a guideline as a pilot in which the strengths.
Experiences of EPC 2006 Heikki Sirelius JTO School of Management Bucharest 3. of May, 2007.
Gavin MacGregor –Director & Sphamandla Mngomezulu – Graduate.
National Plans for Rare Diseases: Bulgarian experience ICORD meeting – February 2009, Roma, Italy Rumen Stefanov.
NAS/IOM Review of Rare Diseases Research and Orphan Products Development - USA Timothy Cote, M.D., MPH Director, Office of Orphan Products Development.
The Seventh Framework Programme for Research and Technological Development (FP7) supporting innovation Epp Tohver-Bulavs 07. November 2007, Tallinn.
1 Panel 1 – Starting Effective Investor Education Programmes IFIE International Conference Washington Monday, 2 nd March 2009.
EURORDIS Eurordis Position on Research Priorities for Rare Diseases.
Health Reform: Local Safety Net Implications Karen J. Minyard, Ph.D., Executive Director, Georgia Health Policy Center, Georgia State University.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
An Introduction to Genetic Alliance UK’s Work in Scotland Natalie Frankish – Development Officer for Scotland Event:Action Duchenne Scottish Conference.
Agency for Healthcare Research and Quality Advancing Excellence in Health Care The “Centers for Education & Research on Therapeutics” (CERTs)
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
The EEA Grants: Public Health Initiatives Programme Operator Meeting, Lisboa, 5 June 2014 National Health Examination Survey INSEF Carlos Matias.
BioMedical Cluster New opportunities for innovators and investors with Bio-Medical Cluster of Skolkovo Foundation Innovation in Medical Technologies Conference,
Kansas Rural Health Options Project March 6, 2006.
M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 28 – Consumer and Health Protection.
European Patients’ Academy on Therapeutic Innovation – The project is receiving support from the.
The Health Services Research Centre and NAP5
CONTROLLING THE COSTS OF HEMOPHILIA
Support action for innovation mainstreaming within the
Strengthening the foundations of ERA
HPH Strategy Seminar Beijing, China 7 september 2013 Andrea Limbourg
Implementation: the Case of Egypt
RSE Annual General Assembly
National Cancer Center
Presentation transcript:

Rare Diseases Foundation Céline Hubert Pr Nicolas Lévy

Rare diseases in France 3 millions of people concerned More than 200 patients organizations 1260 diagnostic tests available compared to 7000 rare diseases Two national Health governmental plans launched to improve rare diseases care  

1 st National Rare Diseases Plan 10 main stakes Stake n° 1 : Conduct epidemiological research Stake n° 2 : Caracterize rare diseases specificity Stake n° 3 : Improve patients, health workers and general public knowledges Stake n° 4 : Traine physicians to rare diseases diagnosis Stake n° 5 : Organize screening and improve access to diagnostic testing Stake n° 6 : Improve access to specialized units for optimal quality of care Stake n° 7 : Stimulate orphan drugs development Stake n° 8 : Give optimal support to patients Stake n° 9 : Promote research on rare diseases Stake n° 10 : Develop european and international partnerships 134 excellence centers were approved all over France

Rare diseases research weaknesses Are due to : Large number of diseases Rareness of diseases and weak number of patients Scattering of patients all over France Clinical heterogeneity Collection difficulties of clinical information and biological samples Lack of interest of pharmaceutical companies

2 nd National Rare Diseases Plan French Ministry of Health and French Minstry of research launched the 2 nd plan for rare diseases on the 28 th of February 2011:  47 measures for 3 key stakes Stake A : Reinforce quality of care Stake B : Develop research on rare diseases Stake C : Improve european and international partnerships Main actions stake B: Creation of the rare Disease Foundation Creation of a national rare diseases databasis RADICO project (RAre DIsease Cohorts)

Rare diseases Foundation mission

Mission To improve knowledge of rare diseases To structure and to harmonize To coordinate and to federate To develop and to finance Research initiatives on rare diseases in France

Six main fields of action Improvement of the access to ressources Expertise, people, founds, knowledges National Rare diseases databasis and cohortsClinical trialsResearch on Social and Human SciencesEuropean and International CooperationPublic health indicators and epidemiology

Networking Facilitate access tecnological plateforms Finance research projects Facilitate access to human ressources: employees and ressources finding Rare disease national data bank RADICO project management BAMARA/CEMA RA databank management Excellence centers’ registries and data banks sharing Clinical trials ORPHANDEV: clinical trials support unit Develop partnerships between private companies and public organizations Social Sciences & disability research projects « Patients driven research » projects Psycho- sociological impact of rare diseases evaluation Satisfaction survey, post AMM studies European and International cooperation EUROPLAN Contribution to IRDiRC (International Rare Diseases Research Consortium) E-rare & coordination of research projects Public Health indicators development in rare diseases Evaluation of genotype/phenotyp e correlations, incidence and prevalence estimations Rare diseases costs evaluation Return on investments evaluation

Rare diseases Foundation Management Board

Organization 5 founders (2 votes) 8 qualified people in rare diseases field or Health (1 vote) 1 representative of teaching-researchers President Partners Scientific committees Director and associate director Pr Nicolas Levy Céline Hubert Management board The Rare Diseases Foundation is a non-profit private organization

A unique model of alliance 5 founders

Universities and Hospitals involved

8 qualified people, advisors of the Foundation Pr JP Grünfeld Nephrologist Necker Hospital JM Belorgey ENA alumnus Council of State Dr MG Mattei Geneticist Marseille University Pr FN Gilly Surgeon oncologist Lyon University Pr J Kristeva Psychanalist Philosopher Paris VII University Pr G Tchernia Hematologist 2 nd national plan coordinator Direction team Pr Nicolas Lévy Head of medical Genetics department Marseille University-Hospital Marseille University Rare diseases Foundation Director Céline Hubert Operational Director

On dedicated people per region Profil:  Scientist, physician, pharmacist with knowledge of rare diseases field Mission:  Networking of rare diseases field actors  National rare diseases databasis and RADICO project deployment  Promotion of Foundation calls to projects  Facilitation of access to technological plateforms  Fund raising

Scientific committees In charge of the Foundation scientific policy  Researchers and physicians  All medical specialties involved Operational scientific committee french experts of rare disease 4 meetings/year Operational scientific committee french experts of rare disease 4 meetings/year Scientific committee french and international experts 2 meetings/year Experts committees for projects evaluation, (national & international experts)

Expected benefits ? Improvement of patients care, Improvement of our knowledge, More clinical trials conducted, More projects financially supported, Best practices sharing, Facilitated access to innovative technologies, More linked between academic and private research, …

Financial resources Founders financial support, French Ministry of Research financial support, Grants, Public-private partnerships.

Where we are… Rare diseases Foundation creation First management board meeting Press conference and launch at Science Academy Web site launch: Second management board meeting First scientific committee meeting Team hiring First calls for projects Contacts with potential partners 8 th of February th of March 2012 May 2012 May – June 2012 May 2012 On going 22 nd of February th of February 2012